Biobanking: Technologies and Global Markets
The global biobanking market was $141 billion in 2010 and is projected to increase by 30% between 2010 and 2015, at a compound annual growth rate (CAGR) of 5.4%.
Current and projected biobank product forecasts during the forecast period (2010 to 2015) are discussed. Biobanks are playing an important role in new drug development. New products approved by the FDA in 2009 and 2010 are covered, and those products expected to be approved within the forecast period are projected. Due to the timing of the release of this report, the figures for 2010 are estimated, except where actual results have been reported.
The report includes analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This analysis also includes biotechnology companies that are using biobanks to develop new, novel products. This report looks at companies poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on how developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.
Market figures are based on revenues at the manufacturers’ level, and the base year for analysis and projection is 2010. Inflation is not calculated in the projection figures. Trends are assessed based on a number of parameters, including projected sales for existing products, new product introductions, expanded indications for existing products, and finally, for projected changes in the prevalence, diagnosis, and prescription rates for certain diseases.
Included in this report are an overview and forecast of the biobanking market by product, disease category, geographic region or country, and company for the period of 2009 to 2015. The worldwide market is analyzed and data are provided for each disease subsegment. Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.